Skip to Main Content

Paper Details

Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD.
Kidney360
9
2020
Author NameAffiliation
Alan S L YuThe Jared Grantham Kidney Institute, University of Kansas Medical Center
Alan S L YuUniversity of Kansas Medical Center
Andrew N HoofnagleUniversity of Washington
Bryan KestenbaumUniversity of Washington
Bryan KestenbaumKidney Research Institute
Thomas D NolinDepartment of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh
  • 1 - 6

Datasets

Release 1.2